Tab Application Banner
  • Users Online: 391
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Reader Login
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2011| March  | Volume 6 | Issue 1  
    Online since July 27, 2016

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in a tertiary care hospital: A retrospective analysis
Rathindranath Sarkar, Sibaji Paujdar, Sattik Siddhanta, Siwalik Banerjee, Dibyendu De, Kuntal Bhattacharyya, Harekrishna Pal
March 2011, 6(1):7-12
Background: Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) affects mainly elderly males, characterized by acute onset pitting edema of hands, negative rheumatoid factor and excellent result with short course of low dose corticosteroid therapy. Objective: To re-evaluate the clinical, laboratory features, management, and ultimate disease progression of RS3PE cases in rheumatology clinic in tertiary care hospital and compare results with previous literature. Methods: We selected the patients of RS3PE in the Rheumatology clinic, Medical College, Kolkata, between 1 January 2002 and 1 January 2010 and followed them up. Results: Among the cases reviewed 23 were female patients and 12 were male patients with mean (SD) age of 54.74 (3.03) and 58.33 (5.33) years, respectively. Oral Hydroxychloroquine was started in all, giving a satisfactory result in 21 patients; rest of the 14 patients needed additional corticosteroid, to alleviate musculoskeletal symptoms. Baseline mean (SD) C-reactive protein and erythrocyte sedimentation rate were 21.63 (2.08) mg/L and 81.34 (9.29) mm/hr, respectively, and reduced to 3.23 (0.95) mg/L and 17.43 (5.55) mm/hr, respectively, following therapy. During follow-up, musculoskeletal symptoms relapsed in 17 patients, seven (20%) of them were found to be associated with malig- nancy. At the time of last visit during the follow-up period, only four patients developed definite arthropathy (one seronegative rheumatoid arthritis, three undifferentiated spondyloarthropathy), rest of the 31 cases were remitted. Conclusion: Regarding RS3PE, results of our study showed similarity with previous reports excepting the gender. Hydroxychloroquine has been proved as a good steroid-sparing agent in RS3PE. This study supported the association of RS3PE with malignancy in the previous literatures.
[ABSTRACT]   Full text not available  [PDF]  [Mobile Full text]  [EPub]
  609 72 -
Multicenter audit on the use of Leflunomide, in isolation or combination and assessment of adverse effects in rheumatoid arthritis patients
Dinesh Sirisena, Tarnya Marshall, Christopher Deighton, Kuntal Chakravarty
March 2011, 6(1):3-6
Background: Rheumatoid arthritis (RA) is a highly prevalent condition worldwide with significant associated morbidity and disability. In recent decades, disease modifying anti-rheumatic drugs (DMARDs) have been employed as mono or combination therapy to halt disease progression and the sequelaefrom occurring. Due to immunomodulatory effects, the frequency of monitoring adverse effects and termination of medication has long been under scrutiny. Aim: This multicentre audit considered Leflunomide use in clinical practice. Factors considered include the underlying condition treated, starting and maintenance doses, whether it was a mono or combination therapy, side effects reported and monitoring conducted. Methods: A retrospective review of case-notes from Leflunomide-treated patients was conducted at three centres in the UK. A pre-agreed proforma was completed to collect data appropriate to each aim. Results: Four hundred and twenty-seven case-notes were reviewed. Over 95% of patients received it for RA, 20 mg was the commonest loading/maintenance dose and 80% were treated with Leflunomide as mono-therapy. Gastrointestinal symptoms (18%) were the most prevalent side effects with most occurring within the first 6 weeks. A reduction in clinical efficacy was noted in 21% of patients. Monitoring varied significantly at each of the centre but little difference in the outcome was noted. Conclusion: While DMARDs have become first-line treatmentsin RA, increasing evidence suggests that monitoring does not need to be as rigorous as previously believed. This audit highlights a relative advantagein using Leflunomide in terms of dosing, its use as a mono-or combination therapy, side effects, long-term tolerability and monitoring.
[ABSTRACT]   Full text not available  [PDF]  [Mobile Full text]  [EPub]
  507 74 -
Sjögren's syndrome: Infections that may play a role in pathogenesis, mimic the disease, or complicate the patient's course
Robert I Fox, Carla M Fox
March 2011, 6(1):13-25
Sjögren's syndrome (SS) is a systemic autoimmune disorder characterized by lymphocytic infiltration of the lacrimal and salivary glands, leading to dryness of the eyes and mouth. Epidemiologic studies have indicated a role of both genetic and environmental factors in pathogenesis. It is likely that viral infection can create an inflammatory micro- environment that alters the disposition of apoptic fragments that serve as autoantigens. Thus, the search for a single viral agent that is causative is likely to prove difficult. Attention has focused on viruses that have tropism for the sali- vary and lacrimal glands, particularly members of the herpesvirus family. Other infectious agents too may mimic the clinical appearance of SS or complicate the disease. This article reviews the role of infections in patients with Sjogren's syndrome.
[ABSTRACT]   Full text not available  [PDF]  [Mobile Full text]  [EPub]
  496 50 -
Rheumatology in India-caring for the masses
Vinay Ramachandra Joshi
March 2011, 6(1):38-39
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  385 77 -
The spectrum of rheumatic manifestations of HIV Infection in an era of antiretroviral therapy
Vijay Bohra, Krishnan Shanmuganandan
March 2011, 6(1):28-37
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  341 90 -
Monitoring adverse effects of leflunomide: Role of clinical audit
Subramanian Shankar, Yanamandra Uday
March 2011, 6(1):1-2
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  363 62 -
Satyanarayana Swamy Cheekatla, Vikas Agarwal
March 2011, 6(1):26-27
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  345 75 -
Rheumatology quiz
Vivek Arya, Varun Dhir
March 2011, 6(1):40-40
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  308 102 -
International publications of interest from India (December 2010-February 2011)
Vivek Arya
March 2011, 6(1):41-43
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  278 67 -
What is your diagnosis?: An unusual presentation of Pyrexia of unknown origin
Amit Dua, Atul Kakar, Prem Sagar Gupta
March 2011, 6(1):44-45
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  262 44 -
Cryptococcal meningitis in systemic lupus erythematosus- Magnetic resonance imaging is not good
Raghunandan Prasad, Yogesh Preet Singh, Vikas Agarwal, Vinay Kumar Paliwal, Rungmei Silchekama Marak, Rakesh Kumar Gupta
March 2011, 6(1):50-52
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  267 35 -
Hot rheumatology updates: January to March 2011
Sukhbir Uppal
March 2011, 6(1):46-49
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  255 34 -